News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeoStem, Inc. Out-Licenses China Rights For Cancer Immunotherapy To Cellular Biomedicine Group


5/14/2014 9:04:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 13, 2014 -- NeoStem out-licensed exclusive China rights for its liver cancer treatment to Cellular Biomedicine Group of China. The patient-specific cancer immunotherapy, DC-TC, is ready to begin a Phase II trial in patients with hepatocellular carcinoma. CBMG will be responsible for the costs of the trial and most other aspects of the treatment’s development in China. NeoStem, however, will make the regulatory filings and manufacture DC-TC. If all goes well, NeoStem could receive up to $30 million in milestones. More details....

Stock Symbols: (NSDQ: NBS) (OTCQB: CBMG)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES